Trichostatin A, a histone deacetylase (HDAC) inhibitor, has been used in cancer research; it offers a novel approach to treating chemoresistant tumours by enhancing sensitivity to DNA damaging agents [29]. Here, HDAC9 is linked to neoplasm.